Arrowstreet Capital, Limited Partnership Puma Biotechnology, Inc. Transaction History
Arrowstreet Capital, Limited Partnership
- $108 Billion
- Q1 2024
A detailed history of Arrowstreet Capital, Limited Partnership transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Arrowstreet Capital, Limited Partnership holds 230,425 shares of PBYI stock, worth $751,185. This represents 0.0% of its overall portfolio holdings.
Number of Shares
230,425Holding current value
$751,185% of portfolio
0.0%Shares
7 transactions
Others Institutions Holding PBYI
# of Institutions
99Shares Held
29.5MCall Options Held
842KPut Options Held
32.2K-
Vanguard Group Inc Valley Forge, PA3.49MShares$11.4 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.17MShares$10.3 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA2.82MShares$9.18 Million0.78% of portfolio
-
Acadian Asset Management LLC Boston, MA1.96MShares$6.38 Million0.04% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.73MShares$5.64 Million0.01% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $149M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...